OTC Antikörper (AA 51-150)
-
- Target Alle OTC Antikörper anzeigen
- OTC (Ornithine Carbamoyltransferase (OTC))
-
Bindungsspezifität
- AA 51-150
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser OTC Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), ELISA
- Kreuzreaktivität
- Human
- Homologie
- Mouse,Rat,Dog,Cow,Pig,Horse
- Aufreinigung
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from human OTC
- Isotyp
- IgG
- Top Product
- Discover our top product OTC Primärantikörper
-
-
- Applikationshinweise
-
WB 1:300-5000
ELISA 1:500-1000 - Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 μg/μL
- Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- Haltbarkeit
- 12 months
-
- Target
- OTC (Ornithine Carbamoyltransferase (OTC))
- Andere Bezeichnung
- OTC (OTC Produkte)
- Hintergrund
-
Synonyms: OCTD, Ornithine carbamoyltransferase, mitochondrial, Ornithine transcarbamylase, OTCase, OTC
Background: Defects in OTC are the cause of ornithine carbamoyltransferase deficiency (OTCD) [MIM:311250]. OTCD is an X-linked disorder of the urea cycle which causes a form of hyperammonemia. Mutations with no residual enzyme activity are always expressed in hemizygote males by a very severe neonatal hyperammonemic coma that generally proves to be fatal. Heterozygous females are either asymptomatic or express orotic aciduria spontaneously or after protein intake. The disorder is treatable with supplemental dietary arginine and low protein diet. The arbitrary classification of patients into the 'neonatal' group (clinical hyperammonemia in the first few days of life) and 'late' onset (clinical presentation after the neonatal period) has been used to differentiate severe from mild forms.
- Gen-ID
- 5009
- UniProt
- P00480
-